Abstracts tagged "costs"

Abstract Number: 252 • 2019 ACR/ARP Annual Meeting
Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients
Aliza Karpes ¹, Zhigang Duan ², Hui Zhao ², Lincy Lal ³, Wenyaw Chan ³, Maria E. Suárez-Almazor ⁴, Sharon Giordano ², John Swint ³ and Maria Lopez-Olivo², ¹School of Public Health, The University of Texas Health Science Center at Houston, Dallas, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, ⁴Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX
Background/Purpose: To evaluate the sequences of therapeutic drugs used by rheumatoid arthritis (RA) patients whose initial tumor necrosis factor inhibitor (TNFi) therapy failed, as well…
Abstract Number: 1124 • 2019 ACR/ARP Annual Meeting
The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Jennifer Lofland¹, Pamela Berry ², Feng Pan ², Chetan Karyekar ³, Hannah Guiang ⁴, Rebecca McTavish ⁴ and Melissa Thompson ⁴, ¹Janssen Scientific Affairs, LLC, Spring House, PA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Global Services, LLC, Horsham, PA, ⁴Cornerstone Research Group, Inc, Burlington, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. SLE tends to peak during prime working years, resulting in a high economic burden due…
Abstract Number: 1138 • 2019 ACR/ARP Annual Meeting
Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices
Colin Edgerton¹, Janna Radtchenko ² and V. Michael Holers ³, ¹Articularis Healthcare, Charleston, ²Trio Health, La Jolla, CA, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver
Background/Purpose: RA is an autoimmune disease affecting over 1.5 million Americans. Biologic disease-modifying antirheumatic drugs (bDMARDs) expanded treatment choices for RA patients (pts) in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].